Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2021 | Abatacept for prevention of acute GVHD

Kirk Schultz • 15 Mar 2021
EBMT 2021
Abatacept

Abatacept is a selective inhibitor of T cell costimulation. Kirk Schultz, MD, British Columbia Children’s Hospital, Vancouver, Canada, discusses the use of abatacept for the treatment of acute graft-versus-host disease (GvHD), a major cause of death following unrelated-donor (URD) hematopoietic cell transplant (HCT). This interview took place during the 47th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2021.

More from Kirk Schultz

Identifying operational tolerance pathways after SCT & cGvHD immune profiles with machine learning
1:07
Identifying operational tolerance pathways after SCT & cGvHD immune profiles with machine learning
Kirk Schultz • 23 Apr 2023
GvHD biomarker discovery and validation
2:25
GvHD biomarker discovery and validation
Kirk Schultz • 15 Mar 2021
Tackling GvHD together
0:46
Tackling GvHD together
Kirk Schultz • 15 Mar 2021

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals